Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after SingleAutologous Peripheral Stem Cell TransplantationinPatients with Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 486-492

  Sahebi, Firoozeh ^a,c   Frankel, Paul H ^a,b   Farol, Len ^a,c   Krishnan, Amrita Y ^a   Cai, Ji lian ^a,c   Somlo, George ^a   Thomas, Sandra H ^a   Reburiano, Eunicia ^a   Popplewell, Leslie L ^a   Parker, Pablo M ^a   Spielberger, Ricardo T ^a,c   Kogut, Neil M ^a,c   Karanes, Chatchada ^a   Htut, Myo ^a   Ruel, Christopher ^a,b   Duarte, Lupe ^a,b   Murata Collins, Joyce L ^a   Forman, Stephen J ^a  

^a City of Hope ^*  (United States)

^b Clinical Trials Office   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

IMiD; Immunomodulatory drug; Post transplant; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ANXIETY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; CYTOGENETICS; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK EDEMA; HEARING LOSS; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LEUKEMIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; SIDE EFFECT; SINUS BRADYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PYRAZINES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84856949640     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.12.580     Document Type: Article

References (23)

1. Harousseau J.L., Avet-Loiseau H., Attal M., et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009, 27:5720-5726.
2. Harousseau J.L., Palumbo A., Richardson P.G., et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010, 116:3743-3750.
3. Barlogie B., Anaissie E., Haessler J., et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008, 113:355-359.
4. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
5. Spencer A., Prince H.M., Roberts A.W., et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788-1793.
6. Barlogie B., Pineda-Roman M., van Rhee F., et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008, 112:3115-3121.
7. Stewart A.K., Trudel S., Bahlis N.J., et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial. American Society of Hematology Annual Meeting Abstracts. Blood 2010, 116. abstract 39.
8. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
9. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
10. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002, 99:14374-14379.
11. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
12. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
13. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
14. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
15. Morgan G.J., Davies F.E., Gregory W.M., et al. Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results. American Society of Hematology Annual Meeting Abstracts. Blood 2010, 116. abstract 623.
16. Lokhorst H., van der Holt B., Zweegman S., et al. Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high-dose melphalan (HDM) in patients with multiple myeloma (MM). American Society of Hematology Annual Meeting Abstracts. Blood 2008, 112. abstract 157.
17. Hicks L.K., Haynes A.E., Reece D.E., et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008, 34:442-452.
18. McCarthy P.L., Owzar K., Anderson K.C., et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. American Society of Hematology Annual Meeting Abstracts. Blood 2010, 116. abstract 37.
19. Attal M., Lauwers V.C., Marit G., et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02. American Society of Hematology Annual Meeting Abstracts. Blood 2010, 116. abstract 310.
20. Mateos M.-V., Oriol A., Martínez-López J., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11:934-941.
21. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:5101-5109.
22. Mellqvist U.-H., Westin J., Gimsing P., et al. Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial. American Society of Hematology Annual Meeting Abstracts. Blood 2009, 114. abstract 530.
23. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.